Results 251 to 260 of about 115,048 (305)

Chronic Myelomonocytic Leukemia Coexisting with B-cell Chronic Lymphocytic Leukemia

Leukemia & Lymphoma, 2003
Coexistence of B-cell chronic lymphocytic leukemia (B-CLL) and chronic myelomonocytic leukemia (CMML) is an unusal event, and to our knowledge, only four such cases have been reported in the literature. We report a 68-year-old white woman in whom these two diseases were diagnosed concomitantly.
Tadeusz, Robak, Halina, Urbańska-Ryś, Piotr, Smolewski, Ewa, Wawrzyniak, Anna, Korycka, Radzisław, Kordek, Jacek, Bartkowiak   +6 more
openaire   +2 more sources

Rituximab in B-Cell chronic lymphocytic leukemia

Seminars in Oncology, 2003
The monoclonal anti-CD20 antibody rituximab exerts its antitumor activity through a variety of mechanisms, including acting against the cellular defects in apoptosis that give rise to B-chronic lymphocytic leukemia (B-CLL). Phase II clinical studies demonstrated that rituximab, given weekly as a single agent, exhibits significantly less activity in B ...
Thomas S, Lin, Margaret S, Lucas, John C, Byrd   +2 more
openaire   +2 more sources

Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia

Clinical Lymphoma, 2004
Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the Western hemisphere.1 In this disease, a clonal proliferation of neoplastic B lymphocytes accumulates in bone marrow, blood, lymph nodes, liver, and spleen. According to the World Health Organization (WHO) classification, B-cell CLL is a mature (peripheral) B-cell neoplasm ...
Ilan, Shapira, Michael L, Grossbard
openaire   +2 more sources

Histopathology of B-cell chronic lymphocytic leukemia

Hematology/Oncology Clinics of North America, 2004
Histologic and immunohistologic findings of B-cell chronic lymphocytic leukemia/small lymphocytic leukemia are revised in the light of the more recent knowledge on the pathobiology of the disease. The guidelines for the optimal handling of the bioptic samples are provided. The relevance of the examination of trephines and surgical specimens is outlined
PILERI, STEFANO, SABATTINI, ELENA, AGOSTINELLI, CLAUDIO, BODEGA L, ROSSI M, ZINZANI, PIER LUIGI, MARAFIOTI, TERESA   +6 more
openaire   +2 more sources

The Origin of B-Cell Chronic Lymphocytic Leukemia

Seminars in Oncology, 2006
An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen ...
GHIA , PAOLO PROSPERO, Caligaris Cappio F.   +1 more
openaire   +2 more sources

Trisomy 8 in B-cell chronic lymphocytic leukemia

Cancer Genetics and Cytogenetics, 2008
Association between trisomy 8 and myeloid disorders/malignancies has been well documented. We report on two patients with a known history of B-cell chronic lymphocytic leukemia (B-CLL) with bone marrow involvement. In addition to the classic B-CLL cytogenetic abnormalities in one of the patients, both showed a trisomy 8 clone in their bone marrow ...
Olga, Pozdnyakova, Dariusz, Stachurski, Lloyd, Hutchinson, Sapna, Ramakrishnan, Patricia Minehart, Miron   +4 more
openaire   +2 more sources

Multidrug Resistance in B-Cell Chronic Lymphocytic Leukemia

Acta Haematologica, 1995
Multidrug resistance (MDR) was investigated in peripheral blood cells isolated from 40 patients with B cell chronic lymphocytic leukemia (B-CLL) and from 7 healthy volunteers, using a flow cytometric assay that detects cellular efflux of the fluorescent dye rhodamine 123 (Rh 123), which has been demonstrated to be transported from the cell by the P ...
I, Grulois, O, Fardel, B, Drenou, T, Lamy, P Y, Le Prisé, R, Fauchet   +5 more
openaire   +2 more sources

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

Current Oncology Reports, 2017
In recent years, a revolution in the management of chronic lymphocytic leukemia (CLL) has centered on the targeting of the B cell receptor (BCR) signaling pathway. Our improved understanding of the biology of cell signaling in CLL and the development of oral kinase inhibitors directed at the BCR pathway has led to the approval of two new agents and has
Jon E, Arnason, Jennifer R, Brown
openaire   +2 more sources

Alemtuzumab for B-cell chronic lymphocytic leukemia

Expert Review of Anticancer Therapy, 2008
Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleoside analogs.
openaire   +2 more sources

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2008
A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.We investigated 1520 subjects who were 62 to 80 ...
Andy C, Rawstron, Fiona L, Bennett, Sheila J M, O'Connor, Marwan, Kwok, James A L, Fenton, Marieth, Plummer, Ruth, de Tute, Roger G, Owen, Stephen J, Richards, Andrew S, Jack, Peter, Hillmen   +10 more
openaire   +2 more sources